Goldman adds Vertex to U.S. Director’s Cut list; drops IBKR
Goldman Sachs added Vertex Pharmaceuticals to its monthly U.S. Director’s Cut list and removed Interactive Brokers. The list covers 20–25 high-conviction, Buy-rated U.S. stocks and is updated monthly via bottom-up fundamental analysis.